Actively Recruiting
Metronomic Capecitabine in Stage III Gastric Cancer
Led by Fudan University · Updated on 2024-07-08
722
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
CONDITIONS
Official Title
Metronomic Capecitabine in Stage III Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years old
- Confirmed primary adenocarcinoma of gastric cancer at stage III by pathology
- Underwent R0 gastrectomy with D2 lymphadenectomy
- ECOG performance status of 0 or 1 and expected survival over 6 months
- Normal blood counts, liver and kidney function, and electrocardiogram without contraindications (WBC ≥3.5 x 10^9/L, NEU ≥1.2 x 10^9/L, PLT ≥90 x 10^9/L, HGB ≥80 g/L)
You will not qualify if you...
- Previous chemotherapy, radiotherapy, immunotherapy, or targeted therapy
- Presence of multiple primary tumors
- Serious diseases including cardiovascular, respiratory, kidney, or liver conditions or poorly controlled hypertension, diabetes, or mental disorders
- Not eligible for R0 resection and D2 lymph node dissection
- Stage IV gastric cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
Research Team
J
Jing Guo, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here